These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 31999801)

  • 1. Real-world experiences: Efficacy and tolerability of pirfenidone in clinical practice.
    Fang C; Huang H; Guo J; Ferianc M; Xu Z
    PLoS One; 2020; 15(1):e0228390. PubMed ID: 31999801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.
    Feng H; Zhao Y; Li Z; Kang J
    Ther Adv Respir Dis; 2020; 14():1753466620963015. PubMed ID: 33070705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Behr J; Bendstrup E; Crestani B; Günther A; Olschewski H; Sköld CM; Wells A; Wuyts W; Koschel D; Kreuter M; Wallaert B; Lin CY; Beck J; Albera C
    Lancet Respir Med; 2016 Jun; 4(6):445-53. PubMed ID: 27161257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Composite Physiologic Index, Percent Forced Vital Capacity and Percent Diffusing Capacity for Carbon Monoxide Could Be Predictors of Pirfenidone Tolerability in Patients with Idiopathic Pulmonary Fibrosis.
    Konishi S; Arita M; Ito I; Tachibana H; Takaiwa T; Fukuda Y; Watanabe N; Tsubouchi K; Masuda G; Tanaka M; Kourogi Y; Kunimasa K; Nishiyama A; Iwasaku M; Ito A; Tokioka F; Yoshioka H; Hashimoto T; Ishida T
    Intern Med; 2015; 54(22):2835-41. PubMed ID: 26567995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A real-world study of the dosing and tolerability of pirfenidone and its effect on survival in idiopathic pulmonary fibrosis.
    Dhooria S; Agarwal R; Sehgal IS; Prasad KT; Muth V; Garg M; Bal A; Aggarwal AN; Behera D
    Sarcoidosis Vasc Diffuse Lung Dis; 2020; 37(2):148-157. PubMed ID: 33093778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early Experience of Pirfenidone in Daily Clinical Practice in Belgium and The Netherlands: a Retrospective Cohort Analysis.
    Wijsenbeek MS; Grutters JC; Wuyts WA
    Adv Ther; 2015 Jul; 32(7):691-704. PubMed ID: 26173796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of pirfenidone in severe Idiopathic Pulmonary Fibrosis: A real-world observational study.
    Tzouvelekis A; Ntolios P; Karampitsakos T; Tzilas V; Anevlavis S; Bouros E; Steiropoulos P; Koulouris N; Stratakos G; Froudarakis M; Bouros D
    Pulm Pharmacol Ther; 2017 Oct; 46():48-53. PubMed ID: 28843616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world safety and effectiveness of pirfenidone and nintedanib in the treatment of idiopathic pulmonary fibrosis: a systematic review and meta-analysis.
    Kou M; Jiao Y; Li Z; Wei B; Li Y; Cai Y; Wei W
    Eur J Clin Pharmacol; 2024 Oct; 80(10):1445-1460. PubMed ID: 38963453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and safety of pirfenidone for idiopathic pulmonary fibrosis.
    Marcos Ribes B; Sancho-Chust JN; Talens A; Arlandis M; Herraiz P; Chiner E; Aznar T
    Eur J Hosp Pharm; 2020 Nov; 27(6):350-354. PubMed ID: 33020058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment.
    Nathan SD; Costabel U; Albera C; Behr J; Wuyts WA; Kirchgaessler KU; Stauffer JL; Morgenthien E; Chou W; Limb SL; Noble PW
    Respir Med; 2019 Jul; 153():44-51. PubMed ID: 31153107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Effectiveness, Safety, and Tolerability of Pirfenidone in Idiopathic Pulmonary Fibrosis: A Retrospective Study.
    Hanta I; Cilli A; Sevinc C
    Adv Ther; 2019 May; 36(5):1126-1131. PubMed ID: 30900199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Real-life experience with pirfenidone in idiopathic pulmonary fibrosis].
    Yan YJ; Fan YL; Yu SW; Ye Q
    Zhonghua Jie He He Hu Xi Za Zhi; 2018 May; 41(5):327-332. PubMed ID: 29747274
    [No Abstract]   [Full Text] [Related]  

  • 13. Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis.
    Flaherty KR; Fell CD; Huggins JT; Nunes H; Sussman R; Valenzuela C; Petzinger U; Stauffer JL; Gilberg F; Bengus M; Wijsenbeek M
    Eur Respir J; 2018 Aug; 52(2):. PubMed ID: 29946005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A safety evaluation of pirfenidone for the treatment of idiopathic pulmonary fibrosis.
    Anderson A; Shifren A; Nathan SD
    Expert Opin Drug Saf; 2016 Jul; 15(7):975-82. PubMed ID: 27177012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of Pirfenidone in Idiopathic Pulmonary Fibrosis - A Longitudinal Cohort Study.
    Suraj KP; Kumar NK; Jyothi E; Narayan KV; Biju G
    J Assoc Physicians India; 2016 May; 64(5):36-41. PubMed ID: 27735147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Pirfenidone in Advanced Idiopathic Pulmonary Fibrosis.
    Yoon HY; Kim DS; Song JW
    Respiration; 2019; 97(3):242-251. PubMed ID: 30332670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pirfenidone for acute exacerbation of idiopathic pulmonary fibrosis: A retrospective study.
    Furuya K; Sakamoto S; Shimizu H; Sekiya M; Kinoshita A; Isshiki T; Sugino K; Matsumoto K; Homma S
    Respir Med; 2017 May; 126():93-99. PubMed ID: 28427556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of combined therapy with pirfenidone and inhaled N-acetylcysteine for advanced idiopathic pulmonary fibrosis: a case-control study.
    Sakamoto S; Muramatsu Y; Satoh K; Ishida F; Kikuchi N; Sano G; Sugino K; Isobe K; Takai Y; Homma S
    Respirology; 2015 Apr; 20(3):445-52. PubMed ID: 25639750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of pirfenidone and disease severity of idiopathic pulmonary fibrosis: Extended analysis of phase III trial in Japan.
    Taguchi Y; Ebina M; Hashimoto S; Ogura T; Azuma A; Taniguchi H; Kondoh Y; Suga M; Takahashi H; Nakata K; Sugiyama Y; Kudoh S; Nukiwa T;
    Respir Investig; 2015 Nov; 53(6):279-87. PubMed ID: 26521105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Efficacy of Pirfenidone in Advanced Idiopathic Pulmonary Fibrosis: A Nationwide Post-Marketing Surveillance Study in Korean Patients.
    Chung MP; Park MS; Oh IJ; Lee HB; Kim YW; Park JS; Uh ST; Kim YS; Jegal Y; Song JW
    Adv Ther; 2020 May; 37(5):2303-2316. PubMed ID: 32297284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.